Table VIII. CDR3 TCR-conserved amino acid motifs found in AAA lesions of patients with AAA.
| CDR3 Motif | Patient | Normal PBMCs | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AAA00 | AAA02 | AAA03 | AAA04 | AAA06 | AAA07 | AAA09 | AAA10 | AAA12 | AAA14 | ||
| GA | 3/34 (8.8%) | 0/20 (0%) | 16/109 (14.7%) | 7/73 (9.6%) | 0/41 (0%) | 4/40 (10.0%) | 25/59 (42.4%) | 7/88 (8.0%) | 8/45 (17.8%) | 0/29 (0%) | 20/333 (6.0%) |
| GG | 10/34 (29.4%) | 3/20 (15.0%) | 16/109 (14.7%) | 11/73 (15.1%) | 6/41 (14.6%) | 11/40 (27.5%) | 4/59 (6.8%) | 16/88 (18.2%) | 12/45 (26.7%) | 2/29 (6.9%) | 48/333 (14.4%) |
| GL | 4/34 (11.8%) | 3/20 (15.0%) | 29/109 (26.6%) | 7/73 (9.6%) | 25/41 (61.0%) | 0/40 (0%) | 2/59 (3.4%) | 2/88 (2.3%) | 2/45 (4.4%) | 0/29 (0%) | 22/333 (6.6%) |
| GV | 8/34 (23.5%) | 0/20 (0%) | 3/109 (2.8%) | 4/73 (5.5%) | 0/41 (0%) | 0/40 (0%) | 4/59 (6.8%) | 7/88 (8.0%) | 4/45 (8.9%) | 0/29 (0%) | 13/333 (3.9%) |
| LA | 2/34 (5.9%) | 1/20 (5.0%) | 13/109 (11.9%) | 4/73 (5.5%) | 34/41 (82.9%) | 1/40 (2.5%) | 23/59 (39.0%) | 2/88 (2.3%) | 0/45 (0%) | 7/29 (24.1%) | 20/333 (6.0%) |
| RG | 7/34 (20.6%) | 6/20 (30.0%) | 13/109 (11.9%) | 9/73 (12.3%) | 0/41 (0%) | 2/40 (5.0%) | 8/59 (13.6%) | 6/88 (6.9%) | 3/45 (6.7%) | 0/29 (0%) | 26/333 (7.8%) |
| SG | 4/34 (11.8%) | 4/20 (20.0%) | 34/109 (31.2%) | 4/73 (5.5%) | 0/41 (0%) | 7/40 (17.5%) | 26/59 (44.1%) | 27/88 (30.7%) | 6/45 (13.3%) | 1/29 (3.8%) | 34/333 (10.2%) |
| SP | 2/34 (5.9%) | 3/20 (15.0%) | 3/109 (2.8%) | 10/73 (13.7%) | 0/41 (0%) | 10/40 (25.0%) | 3/59 (5.1%) | 17/88 (19.3%) | 6/45(13.3%) | 9/29 (31.0%) | 29/333 (8.7%) |
| SR | 3/34 (8.8%) | 6/20 (30.0%) | 32/109 (29.4%) | 9/73 (12.3%) | 1/41 (2.4%) | 5/40 (12.5%) | 7/59 (11.9%) | 4/88 (4.5%) | 1/45 (2.2%) | 2/29 (6.9%) | 21/333 (6.3%) |
Statistical analysis was performed for AAA versus healthy PBMC. GA, p = 0.0006; GG, p = 0.3192; GL, p = 0.00007; GV, p = 0.2585; LA, p ≤ 0.0001; RG, p = 0.2600; SG, p ≤ 0.0001; SP, p = 0.1565; and SR, p =0.0012.